Dr. Robert D. Siegel
Claim this profileSaint Francis Cancer Center
Expert in Lung Cancer
Expert in Breast Cancer
59 reported clinical trials
116 drugs studied
About Robert D. Siegel
Education:
- Obtained a Medical degree (MD) from the University of California, San Francisco (UCSF) in 1986.
- Completed Residency in Internal Medicine at UCSF, followed by a fellowship in Hematology and Oncology at Stanford University.
Experience:
- Currently serves as a medical oncologist and hematologist at Saint Francis Cancer Center.
- Specializes in the treatment of lung cancer, breast cancer, and gastrointestinal malignancies.
- Engages in clinical research and holds teaching roles within the field of oncology.
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage II
Stage III
2Breast Cancer
Global LeaderHER2 positive
ER positive
ER negative
Affiliated Hospitals
Clinical Trials Robert D. Siegel is currently running
APL-101
for Lung Cancer
This trial is testing APL-101, a new drug, on patients with specific genetic changes in their cancer. These patients often don't respond to typical treatments. The drug aims to block a protein that helps cancer cells grow and spread.
Recruiting1 award Phase 211 criteria
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
More about Robert D. Siegel
Clinical Trial Related6 years of experience running clinical trials · Led 59 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Robert D. Siegel has experience with
- Carboplatin
- Cisplatin
- Nivolumab
- Pembrolizumab
- Paclitaxel
- Intensity-Modulated Radiation Therapy
Breakdown of trials Robert D. Siegel has run
Lung Cancer
Breast Cancer
Breast cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Robert D. Siegel specialize in?
Robert D. Siegel focuses on Lung Cancer and Breast Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage II.
Is Robert D. Siegel currently recruiting for clinical trials?
Yes, Robert D. Siegel is currently recruiting for 10 clinical trials in Greenville South Carolina. If you're interested in participating, you should apply.
Are there any treatments that Robert D. Siegel has studied deeply?
Yes, Robert D. Siegel has studied treatments such as Carboplatin, Cisplatin, Nivolumab.
What is the best way to schedule an appointment with Robert D. Siegel?
Apply for one of the trials that Robert D. Siegel is conducting.
What is the office address of Robert D. Siegel?
The office of Robert D. Siegel is located at: Saint Francis Cancer Center, Greenville, South Carolina 29607 United States. This is the address for their practice at the Saint Francis Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.